Abstract
BACE1, the aspartate protease that generates amyloid-β peptide (Aβ) in the brain of AD (Alzheimer’s disease) patients, has emerged as a pharmaceutically relevant target. Here, a fragment-based in silico approach has been adopted to design novel compounds with increased ligand efficiency for BACE1, before screening for brain permeability and toxicity. Fragments docked to the active site of BACE1 and sorted into two groups using binding energy cut-off, were joined to create novel ligands with binding energy lying in the range between -11.36 kcal/mol and -8.56 kcal/mol. Interestingly, QIN, a known inhibitor of BACE1 with an IC50 of 11nM, when docked to BACE1, shows a binding energy (-9.43 kcal/mol) lying within the range of the novel ligand-BACE1 complexes. The present strategy thus enabled the design of four novel inhibitors of BACE1 with favourable binding energy, brain permeability and no toxicity that might show promise as leads in future.
Keywords: BACE1, inhibitors, fragment, binding energy, design.
Central Nervous System Agents in Medicinal Chemistry
Title:Fragment-based Designing for the Generation of Novel Leads Against BACE1
Volume: 15 Issue: 1
Author(s): Sucharita Das, Sandipan Chakraborty and Soumalee Basu
Affiliation:
Keywords: BACE1, inhibitors, fragment, binding energy, design.
Abstract: BACE1, the aspartate protease that generates amyloid-β peptide (Aβ) in the brain of AD (Alzheimer’s disease) patients, has emerged as a pharmaceutically relevant target. Here, a fragment-based in silico approach has been adopted to design novel compounds with increased ligand efficiency for BACE1, before screening for brain permeability and toxicity. Fragments docked to the active site of BACE1 and sorted into two groups using binding energy cut-off, were joined to create novel ligands with binding energy lying in the range between -11.36 kcal/mol and -8.56 kcal/mol. Interestingly, QIN, a known inhibitor of BACE1 with an IC50 of 11nM, when docked to BACE1, shows a binding energy (-9.43 kcal/mol) lying within the range of the novel ligand-BACE1 complexes. The present strategy thus enabled the design of four novel inhibitors of BACE1 with favourable binding energy, brain permeability and no toxicity that might show promise as leads in future.
Export Options
About this article
Cite this article as:
Das Sucharita, Chakraborty Sandipan and Basu Soumalee, Fragment-based Designing for the Generation of Novel Leads Against BACE1, Central Nervous System Agents in Medicinal Chemistry 2015; 15 (1) . https://dx.doi.org/10.2174/1871524915666150127122546
DOI https://dx.doi.org/10.2174/1871524915666150127122546 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Editor
Infectious Disorders - Drug Targets Recombinant Interleukin-12 for Immunotherapy: A Double-Sided Sword
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Insights into the Pathogenesis and Intervention of Atherosclerosis
Vascular Disease Prevention (Discontinued) Dipeptidyl Peptidase IV Inhibitors: The Next Generation of New Promising Therapies for the Management of Type 2 Diabetes
Current Topics in Medicinal Chemistry PDZ Domain Protein-Protein Interactions: A Case Study with PICK1
Current Topics in Medicinal Chemistry Radionuclide Imaging in Drug Development
Current Pharmaceutical Design Functional and Structural Benefits Induced by Omega-3 Polyunsaturated Fatty Acids During Aging
Current Neuropharmacology An Evaluation of the Effects of Pyridoxal Phosphate in Chlorpromazineinduced Parkinsonism using Mice
Central Nervous System Agents in Medicinal Chemistry An Optimized Approach for Breast Cancer Classification for Histopathological Images Based on Hybrid Feature Set
Current Medical Imaging Hypodopaminergia and “Precision Behavioral Management” (PBM): It is a Generational Family Affair
Current Pharmaceutical Biotechnology The Endocannabinoid/Endovanilloid System and Depression
Current Neuropharmacology Pathophysiology and Prevention of Bronchopulmonary Dysplasia
Current Pediatric Reviews Reducing the Risk of Major Elective Non-cardiac Surgery: Is there a Role for Levosimendan in the Preoperative Optimization of Cardiac Function?
Current Drug Targets Focus on Immunology of Trichinellosis
Medicinal Chemistry Reviews - Online (Discontinued) Proteins Expressed Differently Between Glucose and Glycerol for Schizochytrium limacinum SR21
Current Biotechnology REM Sleep Loss and Recovery Regulates Blood-Brain Barrier Function
Current Neurovascular Research microRNAs-based Predictor Factor in Patients with Migraine-ischemic Stroke
MicroRNA The Growth Hormone Secretagogue Receptor (Ghs-R)
Current Pharmaceutical Design In Search of Novel AMPA Potentiators
Recent Patents on CNS Drug Discovery (Discontinued) Attention Deficit and Hyperactivity Disorder: Controversies of Diagnosis and Safety of Pharmacological and Nonpharmacological Treatment
Current Drug Safety